AU1209995A - Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases - Google Patents

Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases

Info

Publication number
AU1209995A
AU1209995A AU12099/95A AU1209995A AU1209995A AU 1209995 A AU1209995 A AU 1209995A AU 12099/95 A AU12099/95 A AU 12099/95A AU 1209995 A AU1209995 A AU 1209995A AU 1209995 A AU1209995 A AU 1209995A
Authority
AU
Australia
Prior art keywords
treatment
nitric oxide
autoimmune diseases
oxide synthase
synthase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12099/95A
Inventor
J. Brice Weinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University Medical Center
Original Assignee
Duke University Medical Center
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University Medical Center, Duke University filed Critical Duke University Medical Center
Publication of AU1209995A publication Critical patent/AU1209995A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU12099/95A 1993-11-17 1994-11-17 Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases Abandoned AU1209995A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15346993A 1993-11-17 1993-11-17
US153469 1993-11-17
PCT/US1994/013239 WO1995013805A1 (en) 1993-11-17 1994-11-17 Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
AU1209995A true AU1209995A (en) 1995-06-06

Family

ID=22547353

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12099/95A Abandoned AU1209995A (en) 1993-11-17 1994-11-17 Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases

Country Status (5)

Country Link
EP (1) EP0729356A1 (en)
JP (1) JPH09508891A (en)
AU (1) AU1209995A (en)
CA (1) CA2176747A1 (en)
WO (1) WO1995013805A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730930B1 (en) 1995-02-27 1997-04-04 Oreal USE OF NO-SYNTHASE INHIBITORS TO REDUCE THE IRRITANT SKIN EFFECT OF PRODUCTS USED IN THE COSMETIC OR PHARMACEUTICAL FIELD
FR2740339B1 (en) * 1995-10-26 1997-12-05 Oreal USE OF AT LEAST ONE NO-SYNTHASE INHIBITOR IN THE TREATMENT OF SENSITIVE SKIN
DE19549118C2 (en) * 1995-12-29 2000-07-13 Thomas W Stief Hemostasis activation inhibitor and method for inhibiting hemostasis activation in blood or other biological fluids
WO1997045108A1 (en) * 1996-05-30 1997-12-04 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
DE69836197T2 (en) * 1997-08-29 2007-09-06 Innogenetics N.V. METHYLATED SMD HOMOLOGOUS PEPTIDES THAT RESPOND WITH ANTIBODIES FROM SERA OF LIVING WITH SYSTEMIC LUPUS ERYTHEMATODES
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
BR9913526A (en) 1998-09-08 2001-06-05 Monsanto Co Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
US6656925B2 (en) * 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
WO2002060431A1 (en) * 2001-01-30 2002-08-08 Ajinomoto Co., Inc. Remedies/preventives for inflammatory diseases
DE10111050A1 (en) * 2001-03-06 2002-09-12 Beiersdorf Ag Use of substances which prevent the NO-synthase of the warm-blooded organism from exerting its effect, for the preparation of cosmetic or dermatological preparations for the treatment and / or prophylaxis of undesired skin pigmentation
DE10111049A1 (en) * 2001-03-06 2002-09-12 Beiersdorf Ag Cosmetic or dermatological preparations for combating inflammatory disorders or dryness of the skin, containing agents inhibiting the onset of nitrogen monoxide synthase activity
DE10111052A1 (en) * 2001-03-06 2002-09-12 Beiersdorf Ag Cosmetic or dermatological preparations for increasing ceramide biosynthesis, e.g. to prevent dryness, containing agents inhibiting the onset of nitrogen monoxide synthase activity
DE10111054A1 (en) * 2001-03-06 2002-09-12 Beiersdorf Ag Cosmetic or dermatological preparations for reinforcing skin barrier function, e.g. to prevent dryness, containing agents inhibiting the onset of nitrogen monoxide synthase activity
JP2007055900A (en) * 2003-12-15 2007-03-08 Ajinomoto Co Inc Medicinal composition for treating and preventing inflammatory disease
US20190038723A1 (en) * 2016-02-11 2019-02-07 Ohio University Inhibiting UVB-Irradiation Damage By Targeting Nitric Oxide Synthases (cNOS)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059712A (en) * 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
ATE191847T1 (en) * 1991-12-16 2000-05-15 Univ Washington USE OF AMINOGUAMIDINE FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR SUPPRESSING NITROGEN OXIDE FORMATION
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives

Also Published As

Publication number Publication date
EP0729356A1 (en) 1996-09-04
WO1995013805A1 (en) 1995-05-26
CA2176747A1 (en) 1995-05-26
JPH09508891A (en) 1997-09-09

Similar Documents

Publication Publication Date Title
AU7819994A (en) Nitric oxide treatment
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
GB9214857D0 (en) Human nucleic acid fragments and their use
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
AU1209995A (en) Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
HK1045640A1 (en) Novel use of nitric oxide
AU7319994A (en) Nucleotide preparation and uses thereof in wound healing
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU4077193A (en) Alpha-aminoboronic acid peptides and their use as elastase inhibitors
AU3878895A (en) Use of nitric oxide donors in medicine
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
AU4268796A (en) Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase
AU2213197A (en) Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
AU6528494A (en) Nitric oxide combination therapy
GB2294637B (en) Therapeutic compositions and methods of use
AU8473398A (en) 1,3-diaza- heterocycles and their use as nitric oxide synthase inhibitors
AU1870292A (en) Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
AU5773794A (en) 4-amino-3-hydroxycarboxylic acid and their use as anitvirals
IL115505A0 (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
AU3086097A (en) Nitric oxide inhalation for the prophylaxis and treatment of inflammatory response
AU4330197A (en) Protein inhibitor of neuronal nitric oxide synthase
AU4319393A (en) Use of indolocarbazols in aids treatment
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
AU9358398A (en) Use of p-glycoprotein (pgp) inhibitors in the treatment of cancer
AU7066794A (en) Hyaluronic acid fragments and their therapeutic use